Drug intelligence / Profile preview

1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone

Development stage: Unknown
Modality: Small Molecules

Overview

1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone is a synthetic small molecule with the molecular formula C15H20N2O and a molecular weight of approximately 244.33 g/mol[3][4][9]. It features an adamantane moiety linked via an ethanone bridge to an imidazole ring. The compound is classified as experimental and has not been approved for any therapeutic use[1]. Its primary known mechanism of action is inhibition of heme oxygenase 1, an enzyme involved in heme catabolism and cellular stress response pathways[1]. No clinical trials or approved indications are reported for this compound, and it remains at the preclinical/experimental stage.

Other names: 1-(adamantan-1-yl)-2-(imidazol-1-yl)ethanone

Targets

HMOX1 (Heme oxygenase 1)

Beyond the preview

Go deeper on 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone.

Explore the full profile